Myotonic Dystrophy
There are two main types of myotonic dystrophy (DM) — DM type 1 (DM1) and DM type 2 (DM2). DM is also known as Steinert disease, named after Dr. Steinert, who, along with colleagues, first described the classic form in the medical literature in 1909. DM2 is also known as Ricker syndrome or proximal DM or PROMM. DM1 is further classified into congenital DM1, childhood DM1, adulthood DM1, and late- onset DM1.
Myotonic Dystrophy Epidemiology Segmentation in the 7MM
- Total Diagnosed Prevalent Cases
- Age-specific Diagnosed Cases
- Type-specific Diagnosed Cases
- Type-specific Diagnosed Cases of DM1
- Comorbidity-associated Diagnosed Cases
Myotonic Dystrophy Epidemiological Insights Observed in the 7MM (2021)
The total number of incident cases of Myotonic Dystrophy observed in the 7MM was observed to be 80K in the year 2021.
Myotonic Dystrophy Market Insight
The market size of Myotonic Dystrophy in the 7MM was found to be approximately USD 80 million in 2021.
Myotonic Dystrophy Market Strengths
The use of gene therapy in animals has shown significant disease-modifying effects. Hence the dawn of gene therapy for DM is expected soon.
Myotonic Dystrophy Market Opportunities
The current management of the disease includes only symptomatic treatments and does not treat the underlying cause of the disease resulting in higher patient willingness toward expensive therapies like gene therapy.
Myotonic Dystrophy Emerging Drugs and Key Companies
- AMO-02 (tideglusib): AMO Pharma Limited
- Mexiletine: Lupin Ltd
- Pitolisant: Harmony Biosciences, LLC